

QIBA Dynamic Contrast-Enhanced (DCE) MRI Biomarker Committee (BC) Call

Monday, October 25, 2021, at 11 a.m. (CT)

Call Summary

In attendance

Caroline Chaung, MD (Co-Chair)

Hendrik Laue, PhD (Co-Chair)

Trevor Andrews, PhD

Zahra Hosseini, PhD

Nancy Obuchowski, PhD

RSNA staff

Susan Stanfa

Topics Discussed:

- Addressing DCE-MRI Profile Public Comments, with reference to the [Public Comment Resolutions Sheet](#)

Action Items / Next Steps:

- 3.7.2 Subject Selection specification table to be updated to reflect that the Actor who administers the contrast agent should confirm that the patient has no contraindications
- Dr. Laue to verify whether the use of a power injector is FDA cleared for DCE application; if not, the Profile will indicate off-label use
- VFA dynamic and coverage principles will be included both in acquisition tables and in 3.6 Protocol and Reconstruction Design
- Dr. Andrews to contact Philips, Dr. Hosseini to contact Siemens, and Dr. Laue to reach out to GE about post-processing filters in DCE; Dr. Chung to add the vendor-specific details to 3.10.1: Image Data Reconstruction
- Dr. Chung to add text to 3.10 Image Data Reconstruction specification table re: T1-mapping and T1 to DCE alignment, as well as motion correction vs. image registration
- Dr. Laue to consult Drs. Kim and Shiroishi re: artifacts for organs presented in the Profile; Dr. Andrews to look for cases and Dr. Chung to update Profile text
- DCE-MRI BC members invited to work on edits to the [Profile](#) currently in progress

Next call: Monday, November 8, 2021, at 11 a.m. (CT) [2nd & 4th Mondays of each month]

RSNA Staff attempt to capture the names of committee members participating on Zoom calls. However, **if attendees join only by phone, or do not use a recognizable name, identification is not possible.** Participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected in the call summaries.